Gabapentin (All indications)

Language disorders/delay

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S10095
R36750		 Coste (Controls exposed to Lamotrigine, sick) (Mixed indications), 2020 Visits to a speech therapist (mean age of 3.7 years old) during pregnancy (anytime or not specified) retrospective cohort (claims database) exposed to other treatment, sick excluded Adjustment: Yes 0.70 [0.40;1.20]
excluded (control group) 		11/378   157/2,916 168 378
ref
S8517
R28097		 Coste (Controls unexposed, NOS) (Mixed indications), 2020 Health care utilization: Speech therapy (mean age of 3.6 years old) during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: Yes 0.60 [0.40;1.20] 11/378   72,012/1,710,441 72,023 378
ref
S8543
R28381		 Bromley, 2016 Verbal abilities <85 (Wechsler Preschool and Primary Scale of Intelligence (WPPSI) / Wechsler Intelligence Scale for Children (WISC)) (5-9 years old) during pregnancy (anytime or not specified) retrospective cohort (registry) unexposed, sick Adjustment: No 0.98 [0.10;9.53] C 1/14   4/55 5 14
ref
Total 2 studies 0.62 [0.36;1.05] 72,028 392
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Coste (Controls unexposed, NOS) (Mixed indications), 2020Coste, 2020 1 0.60[0.40; 1.20]72,02337894%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Bromley, 2016Bromley, 2016 0.98[0.10; 9.53]5146%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (2 studies) I2 = 0% 0.62[0.36; 1.05]72,0283920.22.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed, NOS) (Mixed indications;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.62[0.36; 1.05]72,0283920%NACoste (Controls unexposed, NOS) (Mixed indications), 2020 Bromley, 2016 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 0.60[0.35; 1.04]72,023378 -NACoste (Controls unexposed, NOS) (Mixed indications), 2020 1 unexposed, sickunexposed, sick 0.98[0.10; 9.53]514 -NABromley, 2016 1 Tags Adjustment   - No  - No 0.98[0.10; 9.53]514 -NABromley, 2016 1   - Yes  - Yes 0.60[0.35; 1.04]72,023378 -NACoste (Controls unexposed, NOS) (Mixed indications), 2020 1 All studiesAll studies 0.62[0.36; 1.05]72,0283920%NACoste (Controls unexposed, NOS) (Mixed indications), 2020 Bromley, 2016 20.210.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 10095

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 0.60[0.35; 1.04]72,023378 -NACoste (Controls unexposed, NOS) (Mixed indications), 2020 1 unexposed, sick controlsunexposed, sick controls 0.98[0.10; 9.53]514 -NABromley, 2016 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 0.70[0.40; 1.21]168378 -NACoste (Controls exposed to Lamotrigine, sick) (Mixed indications), 2020 10.510.01.0